| scholarly article | Q13442814 |
| P50 | author | Andrew Vickers | Q20055453 |
| Donna Ankerst | Q58241772 | ||
| P2093 | author name string | Javier Hernandez | |
| Ian M Thompson | |||
| Lori J Sokoll | |||
| Robin J Leach | |||
| Phyllis J Goodman | |||
| Martin G Sanda | |||
| John T Wei | |||
| Sebastian Bock | |||
| Josef Hoefler | |||
| P2860 | cites work | The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group | Q28749313 |
| A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness | Q33839248 | ||
| Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database | Q34127059 | ||
| The influence of finasteride on the development of prostate cancer | Q34534815 | ||
| Predicting prostate cancer risk through incorporation of prostate cancer gene 3. | Q34809531 | ||
| Radical prostatectomy versus observation for localized prostate cancer | Q36194308 | ||
| Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. | Q36739758 | ||
| The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator | Q37001612 | ||
| Updating risk prediction tools: a case study in prostate cancer | Q37025404 | ||
| Prospective evaluation of operating characteristics of prostate cancer detection biomarkers | Q37252155 | ||
| Models of care and NCCN guideline adherence in very-low-risk prostate cancer. | Q38162362 | ||
| Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial | Q39752227 | ||
| Active surveillance for the management of prostate cancer in a contemporary cohort | Q39843996 | ||
| Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer | Q44199886 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1362-1367 | |
| P577 | publication date | 2014-06-01 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer | |
| P478 | volume | 83 |
| Q59574937 | A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts |
| Q57056566 | A Risk Calculator to Predict the Individual Risk of Conversion From Subthreshold Bipolar Symptoms to Bipolar Disorder I or II in Youth |
| Q63965910 | A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy |
| Q97067005 | A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort |
| Q91432565 | A strategy for high-dimensional multivariable analysis classifies childhood asthma phenotypes from genetic, immunological, and environmental factors |
| Q88870987 | Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population |
| Q38789338 | Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer |
| Q37043425 | Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer |
| Q92402303 | Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study |
| Q57107295 | Are localized prostate cancer biomarkers useful in the clinical practice? |
| Q38568275 | Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy |
| Q47726986 | Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening |
| Q42247367 | Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer |
| Q38726541 | Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review |
| Q48139219 | Atypical small acinar proliferation at index prostate biopsy: rethinking the re-biopsy paradigm |
| Q38697114 | Biomarkers in localized prostate cancer |
| Q37563750 | CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. |
| Q35852107 | Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies |
| Q40417671 | Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel |
| Q39187295 | Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary? |
| Q36238237 | Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort |
| Q40374504 | Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy |
| Q55007094 | Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer. |
| Q104078931 | Diagnostic molecular markers predicting aggressive potential in low-grade prostate cancer |
| Q52841824 | Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. |
| Q95514933 | Editorial Comment |
| Q97533745 | Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort |
| Q40034472 | European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. |
| Q40420181 | European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance. |
| Q30399140 | Evaluation of Prostate Cancer Risk Calculators for Shared Decision Making Across Diverse Urology Practices in Michigan. |
| Q31096808 | External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC. |
| Q40284624 | Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. |
| Q37241363 | Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making |
| Q34470640 | Gleason 6 Prostate Cancer: Translating Biology into Population Health |
| Q54996710 | Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome. |
| Q58576173 | Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study |
| Q98298548 | Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice |
| Q89354488 | Improved Detection of Clinically Significant Prostate Cancer With Software-assisted Systematic Biopsy Using MR/US Fusion in Patients With Negative Prostate MRI |
| Q35940811 | Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators |
| Q50107743 | Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator |
| Q37279076 | Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator |
| Q93001050 | Independent Evaluation of the Respective Predictive Values for High-Grade Prostate Cancer of Clinical Information and RNA Biomarkers after Upfront MRI and Image-Guided Biopsies |
| Q39129035 | Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10. |
| Q90721087 | Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy |
| Q57112037 | MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy |
| Q55139905 | Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic. |
| Q92345413 | Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions |
| Q36495833 | Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests |
| Q37708174 | Novel biomarkers for the detection of prostate cancer |
| Q91142766 | Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS) |
| Q92535853 | Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated? |
| Q98613890 | Predictably unequal: understanding and addressing concerns that algorithmic clinical prediction may increase health disparities |
| Q64085522 | Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis |
| Q40385170 | Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume. |
| Q38259244 | Prostate-specific antigen screening, why have the guidelines changed? |
| Q87888701 | Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy |
| Q47123251 | Recommandations de l’Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate |
| Q90353952 | Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore |
| Q27027085 | Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detection |
| Q37418080 | Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies |
| Q38671170 | Role of mpMRI of the prostate in screening for prostate cancer |
| Q40852349 | Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer |
| Q94521779 | Telomere-based risk models for the early diagnosis of clinically significant prostate cancer |
| Q97531633 | Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States |
| Q35762868 | The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape |
| Q38950693 | The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy. |
| Q38211603 | The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used? |
| Q49546811 | The molecular biology of prostate cancer: current understanding and clinical implications |
| Q38799211 | What is the best way not to treat prostate cancer? |
Search more.